Technology Platform


News Center

The Global First ETa-specific Monoclonal Antibody GMA131 was Approved by the US FDA for the Clinical Study of Diabetic Kidney Disease

DKD, as the leading cause of chronic kidney disease and end stage renal disease (ESRD), is one of the most important complications of diabetes. 

GMAX's GMA106, second generation obesity/T2DM/NASH mAb gives first in human does.

It can be a significant breakthrough as the second generation of drugs in our developmental pipeline for the treatment of obesity and T2DM.